Quotes are at least 15-min delayed:2026/01/01 09:37 EST
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
163.86 
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
0.02/1.70
|
|
Enterprise Value
10.05B
|
| Balance Sheet |
|
Book Value Per Share
37.01
|
| Cash Flow |
|
Cash Flow Yield
0.01
|
| Income Statement |
|
Total Revenue
29.36M
|
|
Operating Revenue Per Share
11.90
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
